Establishment Labs (NASDAQ:ESTA) Price Target Raised to $50.00 at Citigroup

by · The Cerbat Gem

Establishment Labs (NASDAQ:ESTA – Free Report) had its price objective lifted by Citigroup from $45.00 to $50.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other brokerages have also issued reports on ESTA. Stephens reiterated an overweight rating and issued a $68.00 price target on shares of Establishment Labs in a research note on Wednesday, August 7th. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an overweight rating on the stock in a research report on Wednesday, August 7th. Finally, Mizuho increased their target price on shares of Establishment Labs from $65.00 to $70.00 and gave the stock a buy rating in a report on Thursday, June 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Establishment Labs presently has an average rating of Moderate Buy and an average target price of $57.60.

Check Out Our Latest Report on Establishment Labs

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $45.25 on Tuesday. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -14.41 and a beta of 1.20. Establishment Labs has a fifty-two week low of $16.96 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The stock has a fifty day moving average price of $42.62 and a 200-day moving average price of $47.12.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The firm had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. The company’s quarterly revenue was down 9.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.65) earnings per share. As a group, equities analysts anticipate that Establishment Labs will post -2.2 EPS for the current fiscal year.

Insider Activity

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 3,641 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $45.04, for a total transaction of $163,990.64. Following the sale, the chief executive officer now directly owns 210,735 shares of the company’s stock, valued at $9,491,504.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 11.44% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

Hedge funds have recently made changes to their positions in the stock. Hood River Capital Management LLC bought a new stake in Establishment Labs in the second quarter valued at approximately $43,000. Nkcfo LLC acquired a new position in Establishment Labs in the second quarter valued at $227,000. Concurrent Investment Advisors LLC bought a new position in shares of Establishment Labs in the 1st quarter worth about $263,000. SG Americas Securities LLC acquired a new position in shares of Establishment Labs in the 2nd quarter valued at about $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Establishment Labs during the second quarter worth approximately $373,000. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

Read More